{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:20:33Z","timestamp":1793272833625,"version":"4.5.0"},"reference-count":135,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cpet.2024.09.009","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T13:18:19Z","timestamp":1730380699000},"page":"147-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The State-of-the-Art PET Tracers in Glioblastoma and High-grade Gliomas and Implications for Theranostics"],"prefix":"10.1016","volume":"20","author":[{"given":"Jiaqiong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Serafini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russ","family":"Kuker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Ayubcha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Nadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"McKinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abass","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian Q.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cpet.2024.09.009_bib1","first-page":"e21822","article-title":"Reclassification of glioblastoma multiforme according to the 2021 World Health organization classification of central nervous system tumors: a single institution report and practical significance","volume":"14","author":"Stoyanov","year":"2022","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.009_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11060-021-03876-7","article-title":"Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma","volume":"158","author":"Winograd","year":"2022","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.cpet.2024.09.009_bib3","doi-asserted-by":"crossref","first-page":"109663","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib4","first-page":"vdac080","article-title":"Standard clinical approaches and emerging modalities for glioblastoma imaging","volume":"4","author":"Bernstock","year":"2022","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.cpet.2024.09.009_bib5","doi-asserted-by":"crossref","first-page":"6828396","DOI":"10.1155\/2018\/6828396","article-title":"Radiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas","volume":"2018","author":"Zikou","year":"2018","journal-title":"Contrast Media Mol Imaging"},{"issue":"10","key":"10.1016\/j.cpet.2024.09.009_bib6","first-page":"1551","article-title":"FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models","volume":"42","author":"Mochizuki","year":"2001","journal-title":"J\u00a0Nucl Med"},{"issue":"12","key":"10.1016\/j.cpet.2024.09.009_bib7","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.32.12.1323","article-title":"Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography","volume":"32","author":"Di","year":"1982","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.009_bib8","first-page":"196","article-title":"Correlation between FDG-PET uptake and survival in patients with primary brain tumors","volume":"11","author":"Binneboese","year":"2021","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2024.09.009_bib9","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/j.wneu.2023.01.065","article-title":"What is the best preoperative quantitative indicator to differentiate primary central nervous system lymphoma from glioblastoma?","volume":"172","author":"Inoue","year":"2023","journal-title":"World Neurosurg"},{"issue":"12","key":"10.1016\/j.cpet.2024.09.009_bib10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: the bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.009_bib11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/j.semnuclmed.2020.09.002","article-title":"Radiomics in PET\/CT: current status and future AI-based evolutions","volume":"51","author":"Hatt","year":"2021","journal-title":"Semin Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.009_bib12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s13139-017-0500-y","article-title":"Radiomics in oncological PET\/CT: clinical applications","volume":"52","author":"Lee","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2024.09.009_bib13","doi-asserted-by":"crossref","first-page":"101912","DOI":"10.1016\/j.nicl.2019.101912","article-title":"18F-FDG-PET-based radiomics features to distinguish primary central nervous system lymphoma from glioblastoma","volume":"23","author":"Kong","year":"2019","journal-title":"Neuroimage Clin"},{"issue":"5","key":"10.1016\/j.cpet.2024.09.009_bib14","first-page":"518","article-title":"Neuro-Oncology Practice Clinical Debate: FDG PET to differentiate glioblastoma recurrence from treatment-related changes","volume":"8","author":"Parent","year":"2021","journal-title":"Neurooncol Pract"},{"key":"10.1016\/j.cpet.2024.09.009_bib15","doi-asserted-by":"crossref","first-page":"740280","DOI":"10.3389\/fneur.2021.740280","article-title":"Delayed FDG PET provides superior glioblastoma conspicuity compared to conventional image timing","volume":"12","author":"Johnson","year":"2021","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib16","first-page":"vdaa050","article-title":"Value of [18F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab","volume":"2","author":"Graham","year":"2020","journal-title":"Neurooncol Adv"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/jon.12460","article-title":"Role of FDG-PET\/MRI, FDG-PET\/CT, and dynamic susceptibility contrast perfusion mri in differentiating radiation necrosis from tumor recurrence in glioblastomas","volume":"28","author":"Hojjati","year":"2018","journal-title":"J\u00a0Neuroimaging"},{"issue":"5","key":"10.1016\/j.cpet.2024.09.009_bib18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3109\/02841869209088303","article-title":"Measurement of short-term 11C-thymidine activity in human head and neck tumours using positron emission tomography (PET)","volume":"31","author":"van Eijkeren","year":"1992","journal-title":"Acta Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2024.09.009_bib19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MNM.0b013e32834209b5","article-title":"Correlation of 18F-FLT uptake with equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in gastrointestinal cancer","volume":"32","author":"Kameyama","year":"2011","journal-title":"Nucl Med Commun"},{"issue":"9","key":"10.1016\/j.cpet.2024.09.009_bib20","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.2967\/jnumed.110.076794","article-title":"Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells","volume":"51","author":"Plotnik","year":"2010","journal-title":"J\u00a0Nucl Med"},{"issue":"7","key":"10.1016\/j.cpet.2024.09.009_bib21","doi-asserted-by":"crossref","first-page":"e101366","DOI":"10.1371\/journal.pone.0101366","article-title":"Phosphorylation status of thymidine kinase 1 following antiproliferative drug treatment mediates 3'-deoxy-3'-[18F]-fluorothymidine cellular retention","volume":"9","author":"Sala","year":"2014","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.cpet.2024.09.009_bib22","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/S0024-3205(00)00504-X","article-title":"Transport of alovudine (3'-fluorothymidine) into the brain and the cerebrospinal fluid of the rat, studied by microdialysis","volume":"66","author":"Stahle","year":"2000","journal-title":"Life Sci"},{"issue":"12","key":"10.1016\/j.cpet.2024.09.009_bib23","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/01.rlu.0000246820.14892.d2","article-title":"Evaluation of primary brain tumors with FLT-PET: usefulness and limitations","volume":"31","author":"Saga","year":"2006","journal-title":"Clin Nucl Med"},{"issue":"7","key":"10.1016\/j.cpet.2024.09.009_bib24","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1158\/1078-0432.CCR-07-1553","article-title":"Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma","volume":"14","author":"Ullrich","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.cpet.2024.09.009_bib25","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2967\/jnumed.112.104729","article-title":"Correlation of 18F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas","volume":"53","author":"Yamamoto","year":"2012","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2024.09.009_bib26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.nicl.2015.05.012","article-title":"[(18)F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas","volume":"8","author":"Collet","year":"2015","journal-title":"Neuroimage Clin"},{"issue":"30","key":"10.1016\/j.cpet.2024.09.009_bib27","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.2006.10.5825","article-title":"Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study","volume":"25","author":"Chen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2967\/jnumed.111.092387","article-title":"3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab","volume":"53","author":"Schwarzenberg","year":"2012","journal-title":"J\u00a0Nucl Med"},{"issue":"13","key":"10.1016\/j.cpet.2024.09.009_bib29","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1007\/s00259-018-4090-4","article-title":"Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study","volume":"45","author":"Brahm","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.009_bib30","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/ijms24031935","article-title":"Superiority of [11C]methionine over [18F]deoxyglucose for PET imaging of multiple cancer types due to the methionine addiction of cancer","volume":"24","author":"Kubota","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.17116\/neiro20248801163","article-title":"Pozitronnaya emissionnaya tomografiya v sochetanii s komp'yuternoi tomografiei i 11S-metioninom v otsenke metabolizma gliom golovnogo mozga [PET\/CT with 11C-methionine in assessment of brain glioma metabolism]","volume":"88","author":"Vikhrova","year":"2024","journal-title":"Zh Vopr Neirokhir Im N N Burdenko"},{"issue":"12","key":"10.1016\/j.cpet.2024.09.009_bib32","doi-asserted-by":"crossref","first-page":"e3291","DOI":"10.1002\/brb3.3291","article-title":"Resection of positive tissue on methionine-PET is associated with improved survival in glioblastomas","volume":"13","author":"Ohmura","year":"2023","journal-title":"Brain Behav"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.009_bib33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11060-023-04305-7","article-title":"Metabolic delineation of IDH1 wild-type glioblastoma surgical anatomy: how to plan the tumor extent of resection","volume":"162","author":"Altieri","year":"2023","journal-title":"J\u00a0Neuro Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.009_bib34","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/jon.13114","article-title":"Combining methionine-PET and MRI fluid-attenuated inversion-recovery mismatch to determine glioma molecular subtype","volume":"33","author":"Ohmura","year":"2023","journal-title":"J\u00a0Neuroimaging"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.009_bib35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11060-023-04529-7","article-title":"Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [11C]methionine PET","volume":"165","author":"Chen","year":"2023","journal-title":"J\u00a0Neuro Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11060-023-04534-w","article-title":"Comparative evaluation of 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography for distinguishing between primary central nervous system lymphoma and isocitrate dehydrogenase-wildtype glioblastoma","volume":"166","author":"Norikane","year":"2024","journal-title":"J\u00a0Neuro Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.009_bib37","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/ijms21020612","article-title":"Glioblastoma exhibits inter-individual heterogeneity of TSPO and LAT1 expression in neoplastic and parenchymal cells","volume":"21","author":"Cai","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-012-0986-1","article-title":"The role of LAT1 in (18)F-DOPA uptake in malignant gliomas","volume":"111","author":"Youland","year":"2013","journal-title":"J\u00a0Neuro Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib39","doi-asserted-by":"crossref","first-page":"e16093","DOI":"10.1111\/ene.16093","article-title":"Exploring the mechanism of 18F-fluorodopa uptake in recurrent high-grade gliomas: a comprehensive histomole-cular-positron emission tomography analysis","volume":"31","author":"Cobes","year":"2024","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.009_bib40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11060-018-2877-6","article-title":"18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-na\u00efve gliomas: a cross-sectional study","volume":"139","author":"Patel","year":"2018","journal-title":"J\u00a0Neuro Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2024.09.009_bib41","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.ijrobp.2020.06.073","article-title":"Prediction of MGMT status for glioblastoma patients using radiomics feature extraction from 18F-DOPA-PET imaging","volume":"108","author":"Qian","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cpet.2024.09.009_bib42","doi-asserted-by":"crossref","first-page":"699360","DOI":"10.3389\/fonc.2021.699360","article-title":"Additional Value of 18F-FDOPA amino acid analog radiotracer to irradiation planning process of patients with glioblastoma multiforme","volume":"11","author":"Sipos","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2024.09.009_bib43","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ijrobp.2021.03.032","article-title":"Initial results of a phase 2 Trial of 18F-DOPA PET-guided dose-escalated radiation therapy for glioblastoma","volume":"110","author":"Laack","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.009_bib44","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/med.20250","article-title":"Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents","volume":"32","author":"McConathy","year":"2012","journal-title":"Med Res Rev"},{"key":"10.1016\/j.cpet.2024.09.009_bib45","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ymeth.2017.05.019","article-title":"Imaging of amino acid transport in brain tumours: positron emission tomography with O-(2-[18F]fluoroethyl)-L-tyrosine (FET)","volume":"130","author":"Langen","year":"2017","journal-title":"Methods"},{"issue":"12","key":"10.1016\/j.cpet.2024.09.009_bib46","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00259-007-0534-y","article-title":"FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading","volume":"34","author":"P\u00f6pperl","year":"2007","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.cpet.2024.09.009_bib47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejrad.2018.04.003","article-title":"Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI","volume":"103","author":"Pyka","year":"2018","journal-title":"Eur J Radiol"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib48","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/biomedicines11010128","article-title":"Therapy defining at initial diagnosis of primary brain tumor-the role of 18F-FET PET\/CT and MRI","volume":"11","author":"Nagy","year":"2023","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.cpet.2024.09.009_bib49","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.2967\/jnumed.123.265725","article-title":"Automated brain tumor detection and segmentation for treatment response assessment using amino acid PET","volume":"64","author":"Gutsche","year":"2023","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2024.09.009_bib50","article-title":"O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) PET as a potential selection tool for second surgery in glioblastoma patients","author":"Santonocito","year":"2023","journal-title":"J\u00a0Neurosurg Sci"},{"issue":"6","key":"10.1016\/j.cpet.2024.09.009_bib51","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/02688697.2019.1639615","article-title":"Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients","volume":"35","author":"Kristin Schmitz","year":"2021","journal-title":"Br J Neurosurg"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib52","first-page":"56","article-title":"Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET\/CT in prostate carcinoma","volume":"48","author":"Schuster","year":"2007","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.009_bib53","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1097\/RLU.0000000000002432","article-title":"18F-Fluciclovine PET\/CT detection of recurrent prostate carcinoma in patients with serum PSA \u2264 1 ng\/mL after definitive primary treatment","volume":"44","author":"England","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2024.09.009_bib54","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.brainres.2013.08.037","article-title":"Comparative evaluation of transport mechanisms of trans-1-amino-3-[1\u2078F]fluorocyclobutanecarboxylic acid and L-[methyl-11C]methionine in human glioma cell lines","volume":"1535","author":"Ono","year":"2013","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.009_bib55","first-page":"331","article-title":"Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors","volume":"40","author":"Shoup","year":"1999","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2024.09.009_bib56","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.wneu.2018.07.231","article-title":"Fluciclovine, anti-1-amino-3-[18F]-fluorocyclobutane-1-carboxylic acid: a novel radiotracer for meningioma","volume":"119","author":"Nguyen","year":"2018","journal-title":"World Neurosurg"},{"key":"10.1016\/j.cpet.2024.09.009_bib57","doi-asserted-by":"crossref","first-page":"989.e1","DOI":"10.1016\/j.wneu.2017.08.085","article-title":"Multimodal 18F-Fluciclovine PET\/MRI and ultrasound-guided neurosurgery of an anaplastic oligodendroglioma","volume":"108","author":"Karlberg","year":"2017","journal-title":"World Neurosurg"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib58","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1097\/RLU.0000000000002777","article-title":"Pituitary adenoma on 18F-fluciclovine PET\/CT","volume":"45","author":"Wang","year":"2020","journal-title":"Clin Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2024.09.009_bib59","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s12149-016-1102-y","article-title":"Phase IIa clinical study of [18F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors","volume":"30","author":"Kondo","year":"2016","journal-title":"Ann Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13550-018-0415-3","article-title":"[18F]Fluciclovine PET discrimination between high- and low-grade gliomas","volume":"8","author":"Parent","year":"2018","journal-title":"EJNMMI Res"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.009_bib61","first-page":"85","article-title":"Diagnosis of brain tumors using amino acid transport PET imaging with 18F-fluciclovine: a comparative study with L-methyl-11C-methionine PET Imaging","volume":"5","author":"Tsuyuguchi","year":"2017","journal-title":"Asia Ocean J Nucl Med Biol"},{"issue":"6","key":"10.1016\/j.cpet.2024.09.009_bib62","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2967\/jnumed.122.264812","article-title":"Distinguishing progression from pseudoprogression in glioblastoma using 18F-Fluciclovine PET","volume":"64","author":"Nabavizadeh","year":"2023","journal-title":"J\u00a0Nucl Med"},{"issue":"14","key":"10.1016\/j.cpet.2024.09.009_bib63","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.3390\/cancers14143485","article-title":"Exploratory analysis of serial 18F-fluciclovine PET-CT and multiparametric MRI during chemoradiation for glioblastoma","volume":"14","author":"Fatania","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.cpet.2024.09.009_bib64","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3389\/fonc.2018.00623","article-title":"Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis","volume":"8","author":"Hupe","year":"2018","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2024.09.009_bib65","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.31557\/APJCP.2023.24.5.1797","article-title":"Prostate-specific membrane antigen (PSMA) expression in the neovasculature of high grade gliomas (Histopathological and Immunohistochemical Study)","volume":"24","author":"Abdel Maguid","year":"2023","journal-title":"Asian Pac J Cancer Prev"},{"issue":"11","key":"10.1016\/j.cpet.2024.09.009_bib66","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.3390\/biomedicines11113095","article-title":"PSMA-expression is highly associated with histological subtypes of renal cell carcinoma: potential implications for theranostic approaches","volume":"11","author":"Bui","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib67","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/a-1638-9429","article-title":"Expression of prostate specific membrane antigen (PSMA) in breast cancer","volume":"82","author":"Unger","year":"2022","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib68","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/RLU.0000000000001451","article-title":"Diagnostic value of 68Ga PSMA-11 PET\/CT imaging of brain tumors-preliminary analysis","volume":"42","author":"Sasikumar","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2024.09.009_bib69","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.radcr.2022.03.050","article-title":"Incidental prostate-specific membrane antigen-avid glioblastoma detected on 68Ga-prostate-specific membrane antigen PET\/CT","volume":"17","author":"Jiang","year":"2022","journal-title":"Radiol Case Rep"},{"issue":"12","key":"10.1016\/j.cpet.2024.09.009_bib70","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1097\/RLU.0000000000004903","article-title":"68 Ga-PSMA-11 PET\/CT imaging in brain gliomas and its correlation with clinicopathological prognostic parameters","volume":"48","author":"Verma","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"22","key":"10.1016\/j.cpet.2024.09.009_bib71","doi-asserted-by":"crossref","first-page":"16208","DOI":"10.3390\/ijms242216208","article-title":"Comparison between [68Ga]Ga-PSMA-617 and [18F]FET PET as imaging biomarkers in adult recurrent glioblastoma","volume":"24","author":"Brighi","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.cpet.2024.09.009_bib72","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3390\/diagnostics12071665","article-title":"Diagnostic accuracy of PET\/CT or PET\/MRI Using PSMA-targeting radiopharmaceuticals in high-grade gliomas: a systematic review and a bivariate meta-analysis","volume":"12","author":"Muoio","year":"2022","journal-title":"Diagnostics"},{"issue":"8","key":"10.1016\/j.cpet.2024.09.009_bib73","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/RLU.0000000000004716","article-title":"Discriminating inflammatory radiation-related changes from early recurrence in patients with glioblastomas: a preliminary analysis of 68 Ga-PSMA-11 PET\/CT Compared with 18 F-FDOPA PET\/CT","volume":"48","author":"Moreau","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2024.09.009_bib74","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00234-021-02828-2","article-title":"Ga-68 PSMA PET\/CT in recurrent high-grade gliomas: evaluating PSMA expression in\u00a0vivo","volume":"64","author":"Kumar","year":"2022","journal-title":"Neuroradiology"},{"issue":"1139","key":"10.1016\/j.cpet.2024.09.009_bib75","doi-asserted-by":"crossref","first-page":"20220049","DOI":"10.1259\/bjr.20220049","article-title":"Is there any additional benefit of 68Ga-PSMA PET on radiotherapy target volume definition in patients with glioblastoma?","volume":"95","author":"\u015eahin","year":"2022","journal-title":"Br J Radiol"},{"issue":"10","key":"10.1016\/j.cpet.2024.09.009_bib76","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1097\/RLU.0000000000001769","article-title":"Prostate-specific membrane antigen-targeted imaging with [18F]DCFPyL in high-grade gliomas","volume":"42","author":"Salas Fragomeni","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"51","key":"10.1016\/j.cpet.2024.09.009_bib77","doi-asserted-by":"crossref","first-page":"36505","DOI":"10.1074\/jbc.274.51.36505","article-title":"Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts","volume":"274","author":"Park","year":"1999","journal-title":"J\u00a0Biol Chem"},{"issue":"6","key":"10.1016\/j.cpet.2024.09.009_bib78","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1158\/1078-0432.CCR-06-1746","article-title":"Clinical implications of fibroblast activation protein in patients with colon cancer","volume":"13","author":"Henry","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"5\u20136","key":"10.1016\/j.cpet.2024.09.009_bib79","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/prca.201300095","article-title":"Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy","volume":"8","author":"Hamson","year":"2014","journal-title":"Proteomics Clin Appl"},{"issue":"10","key":"10.1016\/j.cpet.2024.09.009_bib80","doi-asserted-by":"crossref","first-page":"13961","DOI":"10.1007\/s13277-016-5274-9","article-title":"Fibroblast activation protein alpha is expressed by transformed and stromal cells and is associated with mesenchymal features in glioblastoma","volume":"37","author":"Busek","year":"2016","journal-title":"Tumour Biol"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.009_bib81","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1515\/bc.2010.119","article-title":"Expression and role of the cell surface protease seprase\/fibroblast activation protein-\u03b1 (FAP-\u03b1) in astroglial tumors","volume":"392","author":"Mentlein","year":"2011","journal-title":"Biol Chem"},{"issue":"13","key":"10.1016\/j.cpet.2024.09.009_bib82","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.3390\/cancers13133304","article-title":"Fibroblast activation protein expressing mesenchymal cells promote glioblastoma angiogenesis","volume":"13","author":"Balaziova","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.009_bib83","doi-asserted-by":"crossref","first-page":"e220749","DOI":"10.1148\/radiol.220749","article-title":"Fapi PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease","volume":"306","author":"Mori","year":"2023","journal-title":"Radiology"},{"issue":"12","key":"10.1016\/j.cpet.2024.09.009_bib84","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1007\/s00259-019-04444-y","article-title":"IDH-wildtype glioblastomas and grade III\/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET\/CT","volume":"46","author":"R\u00f6hrich","year":"2019","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.009_bib85","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1097\/RLU.0000000000004504","article-title":"Interesting findings in 68 Ga-FAPI-46 PET\/CT imaging in a patient with glioblastoma multiforme","volume":"48","author":"Mohammadzadeh Kosari","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2024.09.009_bib86","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2967\/jnumed.120.253062","article-title":"Impact of 68Ga-FAPI PET\/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas","volume":"62","author":"R\u00f6hrich","year":"2021","journal-title":"J\u00a0Nucl Med"},{"issue":"22","key":"10.1016\/j.cpet.2024.09.009_bib87","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.3390\/cancers14225566","article-title":"Performance and prospects of [68Ga]Ga-FAPI PET\/CT scans in lung cancer","volume":"14","author":"Borgonje","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.009_bib88","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3390\/cancers15041193","article-title":"The superiority of fibroblast activation protein inhibitor (FAPI) PET\/CT versus FDG PET\/CT in the diagnosis of various malignancies","volume":"15","author":"Dong","year":"2023","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.cpet.2024.09.009_bib89","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","article-title":"Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients","volume":"61","author":"Meyer","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2024.09.009_bib90","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1021\/acssensors.1c01316","article-title":"Rational design, pharmacomodulation, and synthesis of [68Ga]Ga-Alb-FAPtp-01, a selective tumor-associated fibroblast activation protein tracer for PET imaging of glioma","volume":"6","author":"Lin","year":"2021","journal-title":"ACS Sens"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib91","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12880-022-00952-w","article-title":"Performance of 18 F-FAPI PET\/CT in assessing glioblastoma before radiotherapy: a pilot study","volume":"22","author":"Yao","year":"2022","journal-title":"BMC Med Imag"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.009_bib92","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2024.09.009_bib93","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.3390\/cancers12092511","article-title":"Radioresistance in glioblastoma and the development of radiosensitizers","volume":"12","author":"Ali","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib94","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12885-024-12017-y","article-title":"p53\/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme","volume":"24","author":"Meng","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cpet.2024.09.009_bib95","doi-asserted-by":"crossref","first-page":"216792","DOI":"10.1016\/j.canlet.2024.216792","article-title":"Hypoxia effects on glioblastoma progression through YAP\/TAZ pathway regulation","volume":"588","author":"Castillo","year":"2024","journal-title":"Cancer Lett"},{"issue":"5","key":"10.1016\/j.cpet.2024.09.009_bib96","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/stem.415","article-title":"Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma","volume":"28","author":"Pistollato","year":"2010","journal-title":"Stem Cell"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.009_bib97","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1084\/jem.20101470","article-title":"Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme","volume":"208","author":"Wolf","year":"2011","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.009_bib98","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11060-012-0923-3","article-title":"Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide","volume":"109","author":"Sun","year":"2012","journal-title":"J\u00a0Neuro Oncol"},{"issue":"20","key":"10.1016\/j.cpet.2024.09.009_bib99","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.4161\/cc.8.20.9701","article-title":"The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype","volume":"8","author":"Heddleston","year":"2009","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.009_bib100","doi-asserted-by":"crossref","first-page":"665","DOI":"10.7150\/thno.41692","article-title":"Glioma stem cells and their roles within the hypoxic tumor microenvironment","volume":"11","author":"Boyd","year":"2021","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.cpet.2024.09.009_bib101","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2967\/jnumed.115.158717","article-title":"18F-Fluoromisonidazole quantification of hypoxia in human cancer patients using image-derived blood surrogate tissue reference regions","volume":"56","author":"Muzi","year":"2015","journal-title":"J\u00a0Nucl Med"},{"issue":"8","key":"10.1016\/j.cpet.2024.09.009_bib102","first-page":"1088","article-title":"The roles of hypoxia imaging using 18F-fluoromisonidazole positron emission tomography in glioma treatment","volume":"8","author":"Hirata","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"9","key":"10.1016\/j.cpet.2024.09.009_bib103","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1158\/1078-0432.CCR-07-4995","article-title":"Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival","volume":"14","author":"Spence","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.cpet.2024.09.009_bib104","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00259-017-3677-5","article-title":"[18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis","volume":"44","author":"Bekaert","year":"2017","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib105","doi-asserted-by":"crossref","first-page":"7632","DOI":"10.1038\/s41598-021-84331-5","article-title":"Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET","volume":"11","author":"Huang","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpet.2024.09.009_bib106","doi-asserted-by":"crossref","first-page":"e1364","DOI":"10.1016\/j.wneu.2023.05.030","article-title":"18F-Fluoromisonidazole-positron emission tomography and immunohistochemistry verified tumor oxygenation, stemness, and immunosupportive microenvironment after preoperative neoadjuvant bevacizumab for newly diagnosed glioblastoma","volume":"175","author":"Suzuki","year":"2023","journal-title":"World Neurosurg"},{"issue":"6","key":"10.1016\/j.cpet.2024.09.009_bib107","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s00259-008-0736-y","article-title":"Biodisposition and metabolism of [(18)F]fluorocholine in 9L glioma cells and 9L glioma-bearing Fisher rats","volume":"35","author":"Bansal","year":"2008","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"12","key":"10.1016\/j.cpet.2024.09.009_bib108","doi-asserted-by":"crossref","first-page":"12353","DOI":"10.1007\/s13277-014-2549-x","article-title":"(11)C-choline PET\/CT tumor recurrence detection and survival prediction in post-treatment patients with high-grade gliomas","volume":"35","author":"Li","year":"2014","journal-title":"Tumour Biol"},{"issue":"12","key":"10.1016\/j.cpet.2024.09.009_bib109","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3390\/cancers11121969","article-title":"Imaging and tissue biomarkers of choline metabolism in diffuse adult glioma: 18F-fluoromethylcholine PET\/CT, magnetic resonance spectroscopy, and choline kinase \u03b1","volume":"11","author":"Grech-Sollars","year":"2019","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.009_bib110","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MNM.0000000000000638","article-title":"18F-FCho PET and MRI for the prediction of response in glioblastoma patients according to the RANO criteria","volume":"38","author":"Bolcaen","year":"2017","journal-title":"Nucl Med Commun"},{"issue":"20","key":"10.1016\/j.cpet.2024.09.009_bib111","first-page":"6065","article-title":"A\u00a0head-to-head comparison of 18F-Fluorocholine PET\/CT and Conventional MRI as predictors of outcome in IDH wild-type high-grade gliomas","volume":"11","author":"Garcia Vicente","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib112","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13550-019-0523-8","article-title":"Direct comparison of [11C] choline and [18F] FET PET to detect glioma infiltration: a diagnostic accuracy study in eight patients","volume":"9","author":"Verburg","year":"2019","journal-title":"EJNMMI Res"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.009_bib113","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MNM.0000000000001795","article-title":"Metabolic imaging in recurrent gliomas: comparative performance of 18F-FDOPA, 18F-fluorocholine and 18F-FDG PET\/CT","volume":"45","author":"Sharma","year":"2024","journal-title":"Nucl Med Commun"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.009_bib114","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2967\/jnumed.119.233809","article-title":"Diagnostic accuracy of PET tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma: a systematic review and metaanalysis","volume":"61","author":"de Zwart","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.009_bib115","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2176\/nmc.oa2013-0117","article-title":"Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis","volume":"54","author":"Takenaka","year":"2014","journal-title":"Neurol Med -Chir"},{"issue":"7","key":"10.1016\/j.cpet.2024.09.009_bib116","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3390\/cancers12071868","article-title":"Development of antibody immuno-PET\/SPECT radiopharmaceuticals for imaging of oncological disorders-an update","volume":"12","author":"Dewulf","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.009_bib117","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2967\/jnumed.119.229781","article-title":"First-in-humans imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting","volume":"61","author":"Pandit-Taskar","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.009_bib118","doi-asserted-by":"crossref","first-page":"911","DOI":"10.7150\/thno.89206","article-title":"[89Zr]-CD8 ImmunoPET imaging of glioblastoma multiforme response to combination oncolytic viral and checkpoint inhibitor immunotherapy reveals CD8 infiltration differential changes in preclinical models","volume":"14","author":"Gallegos","year":"2024","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.cpet.2024.09.009_bib119","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1158\/2767-9764.CRC-22-0434","article-title":"Immuno-PET imaging of CD69 visualizes t-cell activation and predicts survival following immunotherapy in murine glioblastoma","volume":"3","author":"Nisnboym","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"3\u20134","key":"10.1016\/j.cpet.2024.09.009_bib120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cytogfr.2008.04.003","article-title":"Immune regulation and control of regulatory T cells by OX40 and 4-1BB","volume":"19","author":"So","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.009_bib121","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1615\/CritRevImmunol.v29.i3.10","article-title":"The role of OX40-mediated co-stimulation in T-cell activation and survival","volume":"29","author":"Redmond","year":"2009","journal-title":"Crit Rev Immunol"},{"issue":"21","key":"10.1016\/j.cpet.2024.09.009_bib122","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1158\/0008-5472.CAN-20-1149","article-title":"Visualization of activated t cells by OX40-immunopet as a strategy for diagnosis of acute graft-versus-host disease","volume":"80","author":"Alam","year":"2020","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.cpet.2024.09.009_bib123","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1158\/1078-0432.CCR-21-1412","article-title":"Whole-body PET imaging of T-cell response to glioblastoma","volume":"27","author":"Nobashi","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.cpet.2024.09.009_bib124","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2326-6066.CIR-20-0678","article-title":"Imaging of T-cell responses in the context of cancer immunotherapy","volume":"9","author":"Xiao","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"15","key":"10.1016\/j.cpet.2024.09.009_bib125","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1073\/pnas.1524212113","article-title":"[18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity","volume":"113","author":"Kim","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.009_bib126","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2967\/jnumed.116.182394","article-title":"Human biodistribution and radiation dosimetry of 18F-Clofarabine, a PET probe targeting the deoxyribonucleoside salvage pathway","volume":"58","author":"Barrio","year":"2017","journal-title":"J\u00a0Nucl Med"},{"issue":"38","key":"10.1016\/j.cpet.2024.09.009_bib127","doi-asserted-by":"crossref","first-page":"10220","DOI":"10.1073\/pnas.1706689114","article-title":"Detection of immune responses after immunotherapy in glioblastoma using PET and MRI","volume":"114","author":"Antonios","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib128","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.cpet.2024.09.009_bib129","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.2967\/jnumed.119.241364","article-title":"Molecular imaging of PD-L1 expression and dynamics with the adnectin-based PET Tracer 18F-BMS-986192","volume":"61","author":"Stutvoet","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"15","key":"10.1016\/j.cpet.2024.09.009_bib130","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.7150\/thno.87168","article-title":"Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction","volume":"13","author":"Chevaleyre","year":"2023","journal-title":"Theranostics"},{"issue":"suppl 2","key":"10.1016\/j.cpet.2024.09.009_bib131","first-page":"4050","article-title":"Fibroblast activation protein (FAP) as a target for radioligand therapy in glioblastoma","volume":"63","author":"Jeanjean","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.009_bib132","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s13139-023-00814-5","article-title":"[177Lu]Lu-DOTAGA.Glu.(FAPi)2 radionuclide therapy: a new treatment option for patients with glioblastoma multiforme","volume":"58","author":"Ballal","year":"2024","journal-title":"Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.cpet.2024.09.009_bib133","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1097\/RLU.0000000000003142","article-title":"177Lu-\/68Ga-PSMA theranostics in recurrent glioblastoma multiforme: proof of concept","volume":"45","author":"Kumar","year":"2020","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2024.09.009_bib134","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2967\/jnumed.116.186338","article-title":"\u03b1-emitters for radiotherapy: from basic radiochemistry to clinical studies-part 1","volume":"59","author":"Poty","year":"2018","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2024.09.009_bib135","doi-asserted-by":"crossref","first-page":"1085245","DOI":"10.3389\/fmed.2022.1085245","article-title":"Targeted alpha therapy for glioblastoma","volume":"9","author":"Kunikowska","year":"2022","journal-title":"Front Med"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859824000804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859824000804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:11:35Z","timestamp":1756293095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859824000804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":135,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1556859824000804"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2024.09.009","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The State-of-the-Art PET Tracers in Glioblastoma and High-grade Gliomas and Implications for Theranostics","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2024.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}